Zacks Investment Research on MSN

CRISPR Therapeutics AG (CRSP) expected to beat earnings estimates: Should you buy?

CRISPR Therapeutics AG (CRSP) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports ...
Zacks Investment Research on MSN

CRISPR Therapeutics AG (CRSP) stock sinks as market gains: Here's why

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $54.65, marking a -1.57% move from the previous day. This move lagged the S&P 500's daily gain of 0.5%. On the other hand, the ...